Legend Biotech is hoping it can ride the biotech IPO wave and take in a cool $100 million for its cell therapy work.
A decade ago, Timothy Springer made an investment on a fledgling biotech company. Now he talks about that bet and other investments.
A Stanford whistleblower complaint alleges that the controversial John Ioannidis study failed to disclose important financial ties and ignored scientistsâ concerns that their antibody test ...
Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and ...
It may seem like an unlikely link but the bodyâs response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology
Consumer transparency measures remain important
Then, with in-depth coverage of the founders and companies that pioneered four industriesâbiotechnology, the Internet, from CAD-CAM to robotics, and modern financeâplus many other âŚ
Two preclinical programs developed by Canadian biotech Northern Biologics have been acquired by privately held German company Boehringer Ingelheim, which